OncoMatch

OncoMatch/Clinical Trials/NCT07218601

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Is NCT07218601 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for non-small cell lung cancer.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT07218601Data as of May 2026

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage I, II, III

Untreated clinical stage I NSCLC amenable to upfront surgery; Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) · Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify